Latest Conference Articles

February 18th 2017, 2:38am

Genitourinary Cancers Symposium (ASCO GU)

Arjun Balar, MD, director, Genitourinary Medical Oncology Progam, NYU Langone Medical Center, discusses the results from the KEYNOTE-053 trial in cisplatin-ineligible advanced urothelial carcinoma.

February 17th 2017, 10:44pm

Genitourinary Cancers Symposium (ASCO GU)

According to preliminary results from an ongoing trial, half of a small group of patients with metastatic castration-resistant prostate cancer had a PSA response during treatment with the PD-L1 inhibitor durvalumab and the PARP inhibitor olaparib (Lynparza).

February 17th 2017, 9:59pm

Genitourinary Cancers Symposium (ASCO GU)

According to results of a prospective clinical study, circulating tumor cell mRNA of full-length androgen receptor (AR) correlated with detection of the AR-V7 variant and with response to AR-targeted therapy for castration-resistant prostate cancer.

February 17th 2017, 9:33pm

Genitourinary Cancers Symposium (ASCO GU)

William Oh, MD, professor, Mount Sinai Hospital, discusses the results from a trial that compared second-line chemotherapy to alternative androgen receptor-targeted agents (ARTA) in patients with metastatic castration-resistant prostate cancer (mCRPC).

February 17th 2017, 7:34pm

Genitourinary Cancers Symposium (ASCO GU)

Josh Armenia, PhD, Memorial Sloan Kettering Cancer Center, discusses the results of an analysis of significantly mutated genes in prostate cancer.

February 17th 2017, 2:50am

Genitourinary Cancers Symposium (ASCO GU)

Andrea B. Apolo, MD, chief of bladder cancer section, National Cancer Institute, discusses the phase I study of cabozantinib (Cabometyx) plus nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with refractory metastatic urothelial carcinoma (mUC) and other genitourinary tumors.

February 17th 2017, 1:18am

Genitourinary Cancers Symposium (ASCO GU)

Hans Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses HyperAcute Renal (HAR) immunotherapy in patients with renal cell carcinoma (RCC).

February 16th 2017, 10:48pm

Genitourinary Cancers Symposium (ASCO GU)

Scott T. Tagawa, MD, Weill Cornell Medicine/New York-Presbyterian, discusses updated results from the IMMU-132 trial in metastatic urothelial cancer (mUC).

February 14th 2017, 3:21am

Genitourinary Cancers Symposium (ASCO GU)

Up to 94% of patients with metastatic castration-resistant prostate cancer have circulating tumor DNA with at least 1 genetic alteration, suggesting ctDNA could be a noninvasive alternative to traditional tumor biopsies and help personalize treatment in this setting.

February 14th 2017, 3:12am

Genitourinary Cancers Symposium (ASCO GU)

Use of antibiotics up to a month before treatment with a checkpoint inhibitor may decrease the efficacy of the immunotherapy agent, results of a retrospective analysis show.

February 14th 2017, 2:59am

Genitourinary Cancers Symposium (ASCO GU)

Some patients who had to stop their PD-1/PD-L1 immunotherapy because of an immune-related adverse event proved to be sustained responders, even after being off the therapy for more than 6 months.

January 25th 2017, 1:47am

Gastrointestinal Cancers Symposium (ASCO GI)

Mark S. Talamonti, MD, clinical professor, NorthShore University HealthSystem, discusses some of the recent surgical advancements in pancreatic cancer.

January 25th 2017, 1:34am

Gastrointestinal Cancers Symposium (ASCO GI)

Christophe Mariette, MD, PhD, surgical oncologist, professor of Surgery, University Hospital of Lille, discusses the results of a study investigating postoperative mortality after patients undergo surgery for esophageal and gastric cancer.

January 22nd 2017, 3:24am

Gastrointestinal Cancers Symposium (ASCO GI)

Arturo Loaiza-Bonilla, MD, medical oncologist, the University of Pennsylvania, discusses a study investigating differences in mutation rates between right- and left-sided colorectal cancer.

January 22nd 2017, 12:04am

Gastrointestinal Cancers Symposium (ASCO GI)

In a single-arm phase II study, cabozantinib demonstrated clinical activity in patients with advanced carcinoid and pancreatic neuroendocrine tumors.

January 22nd 2017, 12:00am

Gastrointestinal Cancers Symposium (ASCO GI)

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses ongoing studies investigating immunotherapy in hepatocellular carcinoma.

January 21st 2017, 8:46pm

Gastrointestinal Cancers Symposium (ASCO GI)

Patients in all age groups derived a survival benefit from treatment of advanced gastric or gastroesophageal juncture cancer with the monoclonal antibody ramucirumab, an analysis of 2 randomized trials showed.

January 21st 2017, 8:05pm

Gastrointestinal Cancers Symposium (ASCO GI)

Patients with advanced hepatocellular carcinoma had a worse survival following progression if they developed new extrahepatic lesions as opposed to other types of progression, supporting the concept of post-progression survival and the influence of different patterns of progression, according to an analysis of the phase III RESORCE trial.

January 21st 2017, 7:48am

Gastrointestinal Cancers Symposium (ASCO GI)

Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses interim safety and clinical activity results in patients with advanced gastric or gastroesophageal junction adenocarcinoma from a multi-cohort phase I study of ramucirumab plus pembrolizumab.

January 21st 2017, 6:51am

Gastrointestinal Cancers Symposium (ASCO GI)

Richard Finn, MD, associate professor of medicine at the UCLA David Geffen School of Medicine, discusses the promise of regorafenib (Stivarga) for the treatment of hepatocellular carcinoma (HCC), as seen in the phase III RESORCE trial.